Abstract
Background
Invasive candidiasis is an important cause of fungal infections in immunocompromised patients, including premature infants. The S-type lectin, galectin-3 (gal3), is increasingly recognized for its role in antifungal host defense. This study tested the hypothesis that tissue gal3 expression is affected by disseminated infection with Candida albicans and that supplementation with gal3 will provide a benefit in this setting.
Methods
To determine the expression of gal3 at the tissue level in response to disseminated infection with C. albicans, adult and neonatal mice were infected using previously established models. End points were chosen that reflected substantive tissue fungal burden but before mortality.
Results
No differences in gal3 were detected in tissues of adult animals relative to uninfected controls. In neonatal animals, gal3 concentration was lower in the spleen of infected animals compared to uninfected. Pretreatment of neonatal mice with recombinant gal3 was associated with reduced mortality and reduced fungal burden in the kidney, spleen, and lung at 24 h following infection.
Conclusion
These findings suggest that gal3 has an active role in host defense against candidiasis and that neonatal animals can benefit from supplementation with this lectin in the setting of disseminated candidiasis.
Similar content being viewed by others
Introduction
Disseminated candidiasis remains an important problem among the immunocompromised. Premature infants are among those at risk, and Candida albicans is the etiological agent in up to 70% of cases.1 Despite antifungal treatment, mortality is common and neurodevelopmental impairment occurs in the majority of survivors.1,2 The susceptibility of these infants is likely through mechanisms that differ from other populations at risk.3 Identifying the complex host defense mechanisms against these infections that may be amenable to modification in favor of the host will advance insight of patient susceptibilities and hasten the development of novel therapeutics.
The host immune system responds to invading pathogens via recognition of specific pathogen-associated molecular patterns (PAMPs). Fungal PAMPs are generally components of the carbohydrate-rich cell wall and include mannan and beta-glucan structures. These PAMPs are identified by pathogen recognition receptors, which are found in a wide assortment of effector cells and involve a variety of receptor types including toll-like receptors (TLRs), integrins, and lectin receptors.4,5
The S-type lectin receptor, galectin-3 (gal3), is one of a family of β-galactoside-binding lectins and has an increasingly apparent role in infection and inflammation.6,7 Among its complex and diverse functions, it is involved in the host response to fungi, in part through its recognition of β-1,2-linked oligomannans, which are a component of the carbohydrate-rich cell wall in C. albicans.8,9 Gal3 is expressed at cell surfaces, extracellular matrix, and in cell secretions by activated macrophages and damaged cells.10,11 It plays an important role in differentiating nonpathogenic from pathogenic fungi.12,13 By recognizing similar antigenic elements on a microbe and host cell but only targeting the microbe, it helps the immune system target those microbes that otherwise would have evaded the immune system due to molecular mimicry.14,15,16
Previous studies have supported a role for gal3 in host defense against disseminated candidiasis.17,18 Mice deficient in gal3 had higher mortality than wild-type mice when infected via tail vein with C. albicans. In addition, the fungal burden was higher on day 3, and the distribution of fungal elements in the kidneys was more diffuse in gal3-deficient mice.17 A potential role for gal3 in susceptibility of preterm infants to candidiasis was suggested by the observation that term and preterm infant express lower gal3 expression in cord blood as compared to adults, and their gal3 expression correlates directly with gestational age.19 To test the hypothesis that a deficient gal3 response contributes to the susceptibility of premature infants to disseminated candidiasis, murine models were used in the current study to compare the tissue gal3 response in adult and newborn mice infected with C. albicans. We also explored whether supplementation of gal3 could attenuate disease in disseminated neonatal candidiasis.
Methods
Growth, maintenance, and preparation of organisms
C. albicans strain SC5314 was used throughout this study. Yeast cultures were maintained on yeast extract, peptone, dextrose (YPD) plates (1% yeast extract, 2% peptone, 2% dextrose, 2% agar). Yeast for injection were prepared by growth for 16 h at 37 °C with vigorous aeration in YPD broth. Cells were collected by centrifugation; washed in sterile, hospital grade-saline; enumerated by hemacytometer; and adjusted to the desired concentration for injection as described below.
Animal models
All animal studies were reviewed and approved by the Lifespan Institutional Animal Care and Use Committee, which oversees the animal care facility where animals were housed for this study. For adult experiments 4–8-week-old wild-type female BALB/c mice were obtained from Charles River Laboratories (Shrewsbury, MA). They were maintained in standard animal facility conditions with unlimited access to food and water. Mice were randomized to receive either 1 × 105 colony-forming units (cfu) of C. albicans or vehicle (sterile saline) by tail-vein injection of 200 µl. Animals were euthanized 48 h postinfection.
For neonatal experiments, timed-pregnant 4–6-week-old BALB/c mice were obtained. Pregnant dams were maintained in individual cages with unlimited access to food and water. Mice were monitored to determine the date of parturition. On day 2 following delivery, pups were randomized to receive intraperitoneal (i.p.) injections in 20 µl of either 5 × 106 cfu of C. albicans or vehicle (sterile saline). Animals were euthanized 24 h postinfection. In a subsequent experiment, pups were delivered and randomized to receive 5 µg carrier-free recombinant mouse gal3 (R&D Systems, Minneapolis, MN) or saline in 20 µl i.p. injection prior to infection with C. albicans as described above. This dose of gal3 was selected because it far exceeds the physiologic concentration of gal3 in mouse pups and would therefore maximize the likelihood of detecting an effect should one exist. The timing of infection with C. albicans following gal3 administration was as short as possible given the logistics of administration and allowing for a short recovery period between i.p. injections. These pups were monitored closely every 3–8 h for signs of illness and were euthanized if moribund. Surviving pups were euthanized at 72 h following infection. To better elucidate the kinetics of dissemination, a time-course experiment was also performed. Pups (n = 5 per treatment group for each time point) were administered gal3 or saline and infected as described above and then euthanized at 24 and 36 h after infection.
In all experiments, at the time of death or euthanasia, organs (kidney, liver, spleen, lung, and brain) were harvested and serum was collected from individual mice. In neonatal mice, sera were pooled from animals in the same group because of low volumes from individual pups. Organs were homogenized by a FastPrep-24 Instrument (MP Biomedical, Inc., Solon, OH) using Lysing Matrix D (Qbiogene; MP Biomedical, Inc.) in 1-ml sterile saline, and appropriate dilutions were plated on YPD containing streptomycin (100 μg/ml) and ampicillin (50 μg/ml). Colonies were enumerated after overnight incubation at 37 °C. Fungal burden was expressed as the cfu/ml/g of the harvested organ.
Quantification of gal3, chemokines, and cytokines
Gal3 levels were quantified using a commercially available gal3 Mouse ELISA Kit (Abcam, Cambridge, MA) according to the manufacturer’s instructions. Cytokines and chemokines in tissue homogenates were quantified using the Bio-Plex Pro™ Mouse Cytokine 23-plex Assay according to the manufacturer’s instructions and analyzed using a Bio-Plex 200 instrument (Bio-Rad, Hercules, CA). The following analytes were interrogated: Eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte- macrophage CSF, interferon-γ, interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, keratinocyte-derived chemokine (KC), monocyte chemoattractant protein-1 (monocyte chemotactic and activating factor), macrophage inflammatory protein (MIP)-1α, MIP-1β, regulated on activation, normal T cell expressed and secreted (RANTES), and tumor necrosis factor (TNF)-α.
Statistical analysis
Gal3 concentration in tissues was analyzed by analysis of variance, and inter-group comparisons were made by the Student–Newman–Keuls Method. Differences in fungal burden were analyzed using a negative binomial model to account for the variability in these data. Survival analysis was by log-rank test. Cytokine/chemokine expression was compared in gal3-treated and control animals by t test. Sigma plot version 13.0 and SAS 9.3 (SAS Institute, Cary, NC) were used for statistical calculations. P values < 0.05 were considered significant.
Results
Gal3 response to disseminated candidiasis in adult mice
Adult mice were injected via tail vein with C. albicans or with vehicle (sterile saline) and were euthanized 48 h after infection. Fungal burden and gal3 were measured in tissue homogenates, and gal3 was also measured in the serum. The infective dose and time point were selected to represent a time when the infection would be well established but before the onset of mortality, based on previous work with this model. Fungal burden was highest in the kidney followed by the spleen, which was consistent with previous experiments (Fig. 1a). Despite differences in fungal burden, the concentration of gal3 in the serum, kidney, liver, spleen, lung, and brain was very similar among infected vs. uninfected animals (Fig. 1b).
Gal3 response to disseminated candidiasis in neonatal mice
Two-day-old mouse pups were injected i.p. with C. albicans or with vehicle (sterile saline), euthanized at 24 h, and fungal burden and gal3 were measured in tissue homogenates. Gal3 was also measured in a single pooled serum sample from all the pups in each group. As with the adult model, the infective dose and time point were selected to represent a time when the infection would be well established but before the onset of mortality, based on previous work with this model. Fungal burden was highest in the spleen and liver, which is characteristic of this model (Fig. 2a). Overall, gal3 expression was similar among infected vs. control pups, with the exception of the spleen, where gal3 expression was significantly reduced in infected relative to control pups (p = 0.04).
Effect of supplementation with recombinant gal3 in neonatal mice infected with C. albicans
The reduction in gal3 in spleens of mouse pups infected with C. albicans together with the previous observation that gal3-deficient mice have increased susceptibility to C. albicans infection17 led us to hypothesize that supplementation with gal3 may afford an advantage to infected neonatal mice. To test this hypothesis, mouse pups were injected i.p. with recombinant gal3 or vehicle followed by infection with C. albicans 2 h later. Animals were closely observed following infection, and surviving animals were euthanized at 72 h. Organs were harvested at the time of death or at 72 h when they were euthanized. Treatment with recombinant gal3 led to a significant decrease in mortality (100–60%) with an increase in median survival from 36 to 70 h as compared to control (Fig. 3, p = 0.02). Uninfected pups that received only gal3 had no signs of illness. Fungal burden at the time of death is depicted in Fig. 4. Although trends toward reduced fungal burden with gal3 treatment could be identified, the only significant reduction in fungal burden at the time of death was seen in the lungs (median 8.7 × 104 cfu/g in gal3 group vs. 1.1 × 105 cfu/g in control, p = 0.048).
Determination of tissue fungal burden at the time of death (or euthanasia) represents a heterogeneous sample in terms of time from infection. These data are therefore unlikely to capture the kinetics of disease progression, particularly considering the difference in survival curves between gal3-treated and control animals (Fig. 3). To better delineate the kinetics of infection, the experiment was repeated, and groups of animal were euthanized at specific time points following infection. Fungal burden in each tissue at 24 h and at 36 h are depicted in Fig. 5. One animal from each group assigned to the 36 h time point died prior to 36 h and was excluded. Significant reductions in fungal burden were noted in the kidney, spleen, and lung at 24 h. The reduction in the kidney was still noted at 36 h, but the lung had increased fungal burden in the gal3 group at 36 h. Fungal burden in the brain was not detectable in the majority of animals at these time points. As expected, the fungal burden at the time of death (Fig. 4) was greater in all the tissues examined than was seen at these time points.
To provide a broad assessment of alterations in the inflammatory response associated with gal3 supplementation, a multiplex cytokine/chemokine assay was performed on the kidney and spleen at 24 and 36 h to capture the time points that showed reduced fungal burden with gal3 treatment. No statistically significant differences were found for any of the 23 proteins measured at either time point (data not shown). Three proteins showed a trend toward lower levels in the spleens harvested at 24 h in gal3-treated mice relative to untreated: G-CSF (mean 499 pg/ml vs. 1812 pg/ml, p = 0.057), KC (mean 203 pg/ml vs. 416 pg/ml, p = 0.077), and MIP-1α (mean 21 pg/ml vs. 203 pg/ml, p = 0.089). At the 36 h time point, splenic concentrations of each of these proteins had decreased in the control animals and were more similar between gal3-treated and control animals.
Discussion
Disseminated candidiasis is a life-threatening complication among immunocompromised patients. These infections occur in the setting of severe illness requiring intensive care, in patients with malignancy and undergoing chemotherapy, and in bone marrow transplant units.20 The importance of the neutrophil in host defense is apparent since neutrophil dysfunction is associated with increased risk, either due to neutropenia or functional impairments in neutrophil effector mechanisms.21 Our focus has been on prematurity as a risk factor for disseminated candidiasis. The characteristics of this patient population that put them at risk are likely to be unique relative to other immunocompromised patients and therefore potentially informative in the development of strategies to reduce risk. The observation that infections caused by the non-albicans species, Candida parapsilosis, are more common in premature infants than in other populations at risk may be one manifestation of this unique host–pathogen interface.22 Additionally, despite the known importance of neutrophil dysfunction, preterm infants are rarely neutropenic when they develop these infections. Further, studies of ex vivo neutrophils isolated from cord blood of term and preterm infants found no differences in either phagocytosis or the capacity to generate an oxidative burst when co-incubated with C. albicans or C. parapsilosis.23 These findings were the basis for the hypothesis that premature infants manifest risk for disseminated candidiasis due to alterations in the developing immune system that indirectly impact neutrophil function. Gal3 is one such candidate. In a variety of experimental settings, gal3 has been shown to be a chemoattractant and to function as an opsonin.24,25 With regard to neutrophil function, exogenous gal3 improves migration, phagocytosis, and the production of reactive oxygen species (ROS) and cytokines.26,27,28,29,30 In a mouse model, gal3-deficient mice infected with a low-lethal dose of C. albicans or with C. parapsilosis had more severe disease manifestations than wild-type mice.17 Finally, we and others have found reduced gal3 concentrations in infant serum relative to healthy adults.17,19
In the current study, we sought to examine the gal3 response to disseminated candidiasis in adult and infant mice at the tissue level. There are important differences between the adult and neonatal models employed in this study. The overall goal was to examine gal3 expression at a time point in each model when they would have substantial fungal burden but before death. The i.p. route was used in neonatal mice because it more closely mimics the mechanism of dissemination that occurs following peritoneal seeding of Candida with intestinal perforation in human preterm infants, an important and common route of infection in this population. This route is also technically more feasible. When adult animals are infected i.p., they clear the infection with limited dissemination and no mortality,31 so the intravenous route was used to ensure disseminated disease. Adults were euthanized at 48 h and neonates at 24 h based on experience with each model and our goal for measurable fungal burden and no mortality. Because of these limitations, however, comparisons between adult and newborn animals are unlikely to be meaningful, and we focused our analysis on infected vs. uninfected animals in each group.
Adult animals infected intravenously did not manifest any differences in tissue concentrations of gal3 compared to uninfected animals at the infective dose and time point studied. Because this study interrogated gal3 expression at the tissue level rather than at the cellular or molecular level, a lack of change in gal3 with infection does not imply that the lectin lacks a role in the host response. On the contrary, a role for gal3 is well supported by the literature and is likely to be quite complex. A role for gal3 in discrimination between pathogenic yeast such as C. albicans and the non-pathogenic Saccharomyces cerevisiae was suggested by a study of macrophage responses. TNF-α production was more strongly induced by C. albicans than S. cerevisiae, and gal3 in association with TLR2 was required for this effect.12 The importance of gal3 in fungal recognition and response in coordination with both TLR2 and dectin-1 was consistent in other experimental settings.13,32 Studies of gal3 in neutrophils suggest that the effects of extracellular and intracellular gal3 may differ. Whereas exogenous gal3 augments recruitment, migration, phagocytosis, and the production of IL-8 and ROS,18,26,30,33 intracellular gal3 has been shown to negatively regulate ROS-dependent killing of C. albicans induced by complement receptor 3.34 Using neutrophil adoptive transfer, this study also suggested that intracellular gal3 downregulates neutrophil effector functions. Further, gal3-deficient mice had reduced mortality and tissue fungal burden than wild-type animals as had also been seen in a previous study.35 These outcomes in gal3-deficient mice are at odds with our results showing gal3-deficient mice to be more susceptible to mortality and higher fungal burdens than wild type17 and with the results of a study involving mannosylation mutants that also showed increased virulence of the wild-type strain in gal3-deficient mice following i.p. injection.36 As suggested by the authors, the discrepant findings may reflect differences in the derivation of the knockout mouse strain and/or effect of different infective C. albicans strains, routes, or doses. Our study employed a “low-lethal dose” that was 5–10-fold less than that used in the other studies.
A number of additional studies of host defense against fungal pathogens have supported a positive role for gal3. A role for gal3 has been identified in generation of a protective T helper type 17 response in experimental models of both candidiasis and cryptococcosis.37,38 It has also been shown to trigger TNF-α production by macrophages and contribute to a fungicidal effect.9 Similar to our studies with disseminated candidiasis in mice, gal3-deficient mice had increased mortality when infected with Cryptococcus neoformans.38 These mice also lacked the increase in IL-17/IL-23 cytokines that was seen in wild-type animals.
The notion that exogenous gal3 may promote effector functions against candidiasis is well supported by our observations with the neonatal mouse model. Infection of mouse pups with C. albicans was associated with decreased expression of gal3 in the spleen. Because mouse pups were infected i.p., the spleen is likely to be an important route of dissemination in this model. This hypothesis is supported by the observation that the spleen bears the highest fungal burden and by previous work with this model showing hyphal elements penetrating the spleen capsule by microscopy.39 These findings led us to speculate that C. albicans may deplete splenic gal3, leading to increased fungal burden and promoting dissemination, and that supplementation of gal3 may reduce disease. Administration of exogenous gal3 substantially reduced mortality in subsequent experiments. Furthermore, the reduction in mortality was associated with reduced fungal burden in the kidney, spleen, and lung at 24 h after infection that persisted to 36 h in the kidney. Together, these data suggest that gal3 supplementation delayed the progression of infection in these animals.
The mechanism by which gal3 provided benefit is likely multifactorial and is the focus of ongoing investigation. As a first step to characterize how gal3 impacts the early inflammatory response to infection, a wide array of cytokines and chemokines were assessed in tissues showing differences in fungal burden. In general, the inflammatory profiles were similar. The majority of information regarding the inflammatory response to disseminated candidiasis in mice has come from adult animals infected via tail vein, and data from newborn mice are extremely limited. Most relevant to the current study, evaluation of the early response to infection in adult mice has highlighted the importance of KC production and its association with progression of pathology in the kidney, the organ most consistently affected in this model.40 Given its role in neutrophil recruitment,41 it is likely that KC expression is important in recruiting leukocytes to the source of infection. The trend toward reduced KC and G-CSF associated with reduced fungal burden that we observed in the spleen at 24 h suggests that the reduction in viable yeast may not be due to more efficient neutrophil recruitment or function but rather may reflect less stimulation for neutrophil recruitment. Because gal3 can directly bind to and kill C. albicans through recognition of β-1,2-linked oligomannans,9 this interaction represents one possible mechanism by which fungal growth may have been inhibited, reducing fungal burden and leading to less inflammatory stimulus. Given the multifaceted effects reported for exogenous gal3 on various components of the innate immune system, multiple mechanisms are possible and likely. Additional experiments focused at the cellular and molecular level within different tissues will better inform the mechanisms at play. Further, defining the timing at which administration of gal3 will alter the course of infection is an important element with potential clinical implications.
References
Benjamin, D. K. Jr. et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 126, e865–e873 (2010).
Benjamin, D. K. Jr et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117, 84–92 (2006).
Arsenault, A. B. & Bliss, J. M. Neonatal candidiasis: new insights into an old problem at a unique host-pathogen interface. Curr. Fungal Infect. Rep. 9, 246–252 (2015).
Cheng, S. C., Joosten, L. A., Kullberg, B. J. & Netea, M. G. Interplay between Candida albicans and the mammalian innate host defense. Infect. Immun. 80, 1304–1313 (2012).
Netea, M. G., Brown, G. D., Kullberg, B. J. & Gow, N. A. An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6, 67–78 (2008).
Vasta, G. R. Roles of galectins in infection. Nat. Rev. Microbiol. 7, 424–438 (2009).
Henderson, N. C. & Sethi, T. The regulation of inflammation by galectin-3. Immunol. Rev. 230, 160–171 (2009).
Fradin, C., Poulain, D. & Jouault, T. β-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3. Infect. Immun. 68, 4391–4398 (2000).
Kohatsu, L., Hsu, D. K., Jegalian, A. G., Liu, F. T. & Baum, L. G. Galectin-3 induces death of Candida species expressing specific β-1,2-linked mannans. J. Immunol. 177, 4718–4726 (2006).
Hughes, R. C. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1473, 172–185 (1999).
Krzeslak, A. & Lipinska, A. Galectin-3 as a multifunctional protein. Cell. Mol. Biol. Lett. 9, 305–328 (2004).
Jouault, T. et al. Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J. Immunol. 177, 4679–4687 (2006).
Esteban, A. et al. Fungal recognition is mediated by the association of dectin-1 and galectin-3 in macrophages. Proc. Natl Acad. Sci. USA 108, 14270–14275 (2011).
Arthur, C. M. et al. Innate immunity against molecular mimicry: examining galectin-mediated antimicrobial activity. Bioessays 37, 1327–1337 (2015).
Baum, L. G., Garner, O. B., Schaefer, K. & Lee, B. Microbe-host interactions are positively and negatively regulated by galectin-glycan interactions. Front. Immunol. 5, 284 (2014).
Cerliani, J. P. et al. Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity. J. Clin. Immunol. 31, 10–21 (2011).
Linden, J. R., De Paepe, M. E., Laforce-Nesbitt, S. S. & Bliss, J. M. Galectin-3 plays an important role in protection against disseminated candidiasis. Med. Mycol. 51, 641–651 (2013).
Linden, J. R., Kunkel, D., Laforce-Nesbitt, S. S. & Bliss, J. M. The role of galectin-3 in phagocytosis of Candida albicans and Candida parapsilosis by human neutrophils. Cell Microbiol. 15, 1127–1142 (2013).
Demmert, M. et al. Galectin-3 in cord blood of term and preterm infants. Clin. Exp. Immunol. 167, 246–251 (2012).
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L. & Kullberg, B. J. Invasive candidiasis. Nat. Rev. Dis. Prim. 4, 18026 (2018).
Erwig, L. P. & Gow, N. A. Interactions of fungal pathogens with phagocytes. Nat. Rev. Microbiol. 14, 163–176 (2016).
Pammi, M., Holland, L., Butler, G., Gacser, A. & Bliss, J. M. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr. Infect. Dis. J. 32, e206–e216 (2013).
Destin, K. G., Linden, J. R., Laforce-Nesbitt, S. S. & Bliss, J. M. Oxidative burst and phagocytosis of neonatal neutrophils confronting Candida albicans and Candida parapsilosis. Early Hum. Dev. 85, 531–535 (2009).
Karlsson, A. et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 19, 16–20 (2009).
Almkvist, J. & Karlsson, A. Galectins as inflammatory mediators. Glycoconj. J. 19, 575–581 (2004).
Nieminen, J., St-Pierre, C. & Sato, S. Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J. Leukoc. Biol. 78, 1127–1135 (2005).
Almkvist, J., Faldt, J., Dahlgren, C., Leffler, H. & Karlsson, A. Lipopolysaccharide-induced gelatinase granule mobilization primes neutrophils for activation by galectin-3 and formylmethionyl-Leu-Phe. Infect. Immun. 69, 832–837 (2001).
Fernandez, G. C. et al. Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology 15, 519–527 (2005).
Fermino, M. L. et al. LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation. PLoS ONE 6, e26004 (2011).
Farnworth, S. L. et al. Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function. Am. J. Pathol. 172, 395–405 (2008).
Vonk, A. G., Netea, M. G., van Krieken, J. H., van der Meer, J. W. & Kullberg, B. J. Delayed clearance of intraabdominal abscesses caused by Candida albicans in tumor necrosis factor-alpha- and lymphotoxin-alpha-deficient mice. J. Infect. Dis. 186, 1815–1822 (2002).
Jawhara, S. et al. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J. Infect. Dis. 197, 972–980 (2008).
Nieminen, J., St-Pierre, C., Bhaumik, P., Poirier, F. & Sato, S. Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J. Immunol. 180, 2466–2473 (2008).
Wu, S. Y. et al. Cell intrinsic galectin-3 attenuates neutrophil ROS-dependent killing of Candida by modulating CR3 downstream Syk activation. Front. Immunol. 8, 48 (2017).
Roman, E. et al. The Cek1-mediated MAP kinase pathway regulates exposure of α-1,2 and β-1,2-mannosides in the cell wall of Candida albicans modulating immune recognition. Virulence. 7, 558–577 (2016).
Courjol, F. et al. β-1,2-Mannosyltransferases 1 and 3 participate in yeast and hyphae O- and N-linked mannosylation and alter Candida albicans fitness during infection. Open Forum Infect. Dis. 2, ofv116 (2015).
Hernandez-Santos, N. & Gaffen, S. L. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11, 425–435 (2012).
Almeida, F. et al. Galectin-3 impacts Cryptococcus neoformans infection through direct antifungal effects. Nat. Commun. 8, 1968 (2017).
Tsai, N. Y., Laforce-Nesbitt, S. S., Tucker, R. & Bliss, J. M. A murine model for disseminated candidiasis in neonates. Pediatr. Res. 69, 189–193 (2011).
MacCallum, D. M., Castillo, L., Brown, A. J., Gow, N. A. & Odds, F. C. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS ONE 4, e6420 (2009).
De Filippo, K., Henderson, R. B., Laschinger, M. & Hogg, N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol. 180, 4308–4315 (2008).
Acknowledgments
The authors are grateful to Matthew Neale and Sunil Shaw for assistance with the experiments and helpful discussions.
Funding
This work was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (P30GM114750) and the Kilguss Research Core at Women & Infants Hospital of Rhode Island.
Author information
Authors and Affiliations
Contributions
Each author has met the authorship requirements as follows: Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data and final approval of the version to be published: all authors; drafting the article or revising it critically for important intellectual content: P.V., R.T., M.E.D.P., J.M.B.
Corresponding author
Ethics declarations
Competing interests
J.M.B. is on the speaker’s board for Mead Johnson Nutritionals. The other authors declare no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Verma, P., Laforce-Nesbitt, S.S., Tucker, R. et al. Galectin-3 expression and effect of supplementation in neonatal mice with disseminated Candida albicans infection. Pediatr Res 85, 527–532 (2019). https://doi.org/10.1038/s41390-019-0279-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41390-019-0279-x